Silence Therapeutics plc (SLN:NASDAQ) closed at $19.65 on October 20, 2026, up 0.33% on the day. The stock trades 0.0% below its 52-week high of $19.65 and 368.9% above its 52-week low of $4.19. Over the past year, it gained 172.3%. Silence Therapeutics plc is part of the Health Care sector.
In 252 trading sessions since October 17, 2025, SLN closed higher on 122 days (48%). Its best day was October 19, 2026 (+125.58%) and its worst was May 15, 2026 (-14.45%). The stock moved 10% or more in a single session 13 times. It opened at least 5% above the previous day's high 2 times.
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial, and its income consists of license fees, milestone and option payments, grant income, and fees from research and development collaborations. Its geographical segments are the United Kingdom and Germany.
Find more stocks like SLN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.